The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.
Open accessAbstract
BACKGROUND: In two of three phase 3 trials, pirfenidone, an oral antifibrotic therapy, reduced disease progression, as measured by the decline in forced vital capacity (FVC) or vital capacity, in patients with idiopathic pulmonary fibrosis; in the third trial, this end point was not achieved. We sought to confirm the beneficial effect of pirfenidone on disease progression in such patients. METHODS: In this phase 3 study, we randomly assigned 555 patients with idiopathic pulmonary fibrosis to receive either oral pirfenidone (2403 mg per day) or placebo for 52 weeks. The primary end point was the change in FVC or death at week 52. Secondary end points were the 6-minute walk distance, progression-free survival, dyspnea, and death from any cause or from idiopathic pulmonary fibrosis. RESULTS: In the pirfenidone group, as compared with the placebo group, there was a relative reduction of 47.9% in the proportion of patients who had an absolute decline of 10 percentage points or more in the percentage of the predicted FVC or who died; there was also a relative increase of 132.5% in the proportion of patients with no decline in FVC (P<0.001). Pirfenidone reduced the decline in the 6-minute walk distance (P=0.04) and improved progression-free survival (P<0.001). There was no significant between-group difference in dyspnea scores (P=0.16) or in rates of death from any cause (P=0.10) or from idiopathic pulmonary fibrosis (P=0.23). However, in a prespecified pooled analysis incorporating results from two previous phase 3 trials, the between-group difference favoring pirfenidone was significant for death from any cause (P=0.01) and from idiopathic pulmonary fibrosis (P=0.006). Gastrointestinal and skin-related adverse events were more common in the pirfenidone group than in the placebo group but rarely led to treatment discontinuation. CONCLUSIONS: Pirfenidone, as compared with placebo, reduced disease progression, as reflected by lung function, exercise tolerance, and progression-free survival, in patients with idiopathic pulmonary fibrosis. Treatment was associated with an acceptable side-effect profile and fewer deaths. (Funded by InterMune; ASCEND ClinicalTrials.gov number, NCT01366209.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Idiopathic pulmonary fibrosis (IPF), the prototype of fibrotic ILDs, carries a prognosis of 3–5 years survival after diagnosis when untreated. Two anti-fibrotic medications (nintedanib and pirfenidone) have been shown to reduce the rate of forced vital capacity (FVC) decline and slow disease progression in patients with a definite usual interstitial pneumonia (UIP) pattern and with a probable UIP pattern on high resolution CT (HRCT).(191–193)”
From Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation. (2021) · cites this paper as [191]
In the citing paper
“However, both have significant adverse effects and neither completely arrest the decline in lung function.”
From Emerging pharmacological options in the treatment of idiopathic pulmonary fibrosis (IPF) (2024) · cites this paper as [13]
In the citing paper
“In three trials with doses that reached 2403 mg/day, pirfenidone effectively reduced FVC decline although had variable reductions in overall mortality and IPF-related mortality [12,13].”
From Emerging pharmacological options in the treatment of idiopathic pulmonary fibrosis (IPF) (2024) · cites this paper as [13]
In the citing paper
“Reported adverse events in the present trial were generally acceptable and largely consistent with events previously reported by participants in the placebo arms of randomized controlled trials in IPF [45,46].”
From Senolytics in idiopathic pulmonary fibrosis: Results from a first-in-human, open-label, pilot study (2019) · cites this paper as [45]
In the citing paper
“FVC is the gold-standard metric for assessing the lung function of patients with IPF and response to therapeutic intervention33–35.”
From A generative AI-discovered TNIK inhibitor for idiopathic pulmonary fibrosis: a randomized phase 2a trial (2025) · cites this paper as [35]
9 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Miller, M. R., Hankinson, J., Brusasco, V., Burgos, F., Casaburi, R., Coates, A., Crapo, R., Enright, P., van der Grinten, C. P. M., Gustafsson, P., et al. (2005) · European Respiratory Journal · doi:10.1183/09031936.05.00034805 · Cited by 15,627
Raghu, G., Collard, H. R., Egan, J. J., Martinez, F. J., Behr, J., Brown, K. K., Colby, T. V., Cordier, J.-F., Flaherty, K. R., Lasky, J. A., et al. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.2009-040gl · Cited by 7,186
Self-citationA sharper Bonferroni procedure for multiple tests of significance
HOCHBERG, Y. (1988) · Biometrika · doi:10.1093/biomet/75.4.800 · Cited by 4,829
Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials
Noble, P. W., Albera, C., Bradford, W. Z., Costabel, U., Glassberg, M. K., Kardatzke, D., King, T. E., Lancaster, L., Sahn, S. A., Szwarcberg, J., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60405-4 · Cited by 2,154
Self-citationDouble-blind, Placebo-controlled Trial of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis
Azuma, A., Nukiwa, T., Tsuboi, E., Suga, M., Abe, S., Nakata, K., Taguchi, Y., Nagai, S., Itoh, H., Ohi, M., et al. (2005) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200404-571oc · Cited by 954
Pirfenidone in idiopathic pulmonary fibrosis
Taniguchi, H., Ebina, M., Kondoh, Y., Ogura, T., Azuma, A., Suga, M., Taguchi, Y., Takahashi, H., Nakata, K., Sato, A., et al. (2010) · European Respiratory Journal · doi:10.1183/09031936.00005209 · Cited by 946
Pirfenidone in idiopathic pulmonary fibrosis: Figure 1–
Swigris, J., & Fairclough, D. (2010) · European Respiratory Journal · doi:10.1183/09031936.00071710 · Cited by 799
Self-citationChanges in Clinical and Physiologic Variables Predict Survival in Idiopathic Pulmonary Fibrosis
Collard, H. R., King, T. E., Bartelson, B. B., Vourlekis, J. S., Schwarz, M. I., & Brown, K. K. (2003) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200211-1311oc · Cited by 764
Self-citationThe Clinical Course of Patients with Idiopathic Pulmonary Fibrosis
Martinez, F. J., Safrin, S., Weycker, D., Starko, K. M., Bradford, W. Z., King, T. E., Flaherty, K. R., Schwartz, D. A., Noble, P. W., Raghu, G., et al. (2005) · Annals of Internal Medicine · doi:10.7326/0003-4819-142-12_part_1-200506210-00005 · Cited by 622
Self-citationKing, T. E., Albera, C., Bradford, W. Z., Costabel, U., Hormel, P., Lancaster, L., Noble, P. W., Sahn, S. A., Szwarcberg, J., Thomeer, M., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60551-1 · Cited by 531
Self-citation
Cited by
Items 2,001–2,100 of 3,967
Kreuter, M., Maher, T. M., Corte, T. J., Molina‐Molina, M., Axmann, J., Gilberg, F., Kirchgaessler, K.-U., & Cottin, V. (2021) · Advances in Therapy · doi:10.1007/s12325-021-02009-w · Cited by 11
Lee, J.-U., Choi, J. S., Kim, M. K., Min, S. A., Park, J., & Park, C. (2022) · The Korean Journal of Internal Medicine · doi:10.3904/kjim.2021.442 · Cited by 11
Khan, M. A., Sherbini, N., Alyami, S., Al-Harbi, A., Alghamdi, M. A., Alrajhi, S., Rajendram, R., & Al-Jahdali, H. H. (2023) · Annals of Thoracic Medicine · doi:10.4103/atm.atm_206_22 · Cited by 14
The Efficacy of Pulmonary Rehabilitation in Patients with Idiopathic Pulmonary Fibrosis
Choi, H. E., Kim, T. H., Jang, J. H., Jang, H. J., Yi, J., Jung, S. Y., Kim, D.-W., & Lee, J. H. (2023) · Life · doi:10.3390/life13020403 · Cited by 12
“Although IPF is chronically progressive, antifibrotic therapy halves the decline in lung function and is effective in preventing acute exacerbation [4,5].”
BackgroundDecoding the role of fatty acids and their metabolites in lung fibrosis
Wygrecka, M., Hadžić, S., Potaczek, D. P., Alexopoulos, I., Agha, E. E., & Schaefer, L. (2023) · Polskie Archiwum Medycyny Wewnętrznej · doi:10.20452/pamw.16520 · Cited by 12
Imaging Features of Idiopathic Interstitial Lung Diseases
Batra, K., & Adams, T. N. (2023) · Journal of Thoracic Imaging · doi:10.1097/rti.0000000000000728 · Cited by 11
Lee, J. H., & Song, J. (2023) · Journal of Thoracic Disease · doi:10.21037/jtd-23-946 · Cited by 15
Therapeutic advances in idiopathic pulmonary fibrosis
George, G., Vaid, U., & Summer, R. S. (2015) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.283 · Cited by 11
Practical management of Idiopathic Pulmonary Fibrosis.
Kishaba, T. (2015) · Sarcoidosis vasculitis and diffuse lung diseases · Cited by 14
Advances in the treatment of idiopathic pulmonary fibrosis
Sergew, A., & Brown, K. M. (2015) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.2015.1102886 · Cited by 12
Multidisciplinary discussion for diagnosis of interstitial lung disease in real life
Guler, S. A., Berezowska, S., Christe, A., et al. (2016) · Swiss Medical Weekly · doi:10.4414/smw.2016.14318 · Cited by 11
Brown, K. K. (2016) · CHEST Journal · doi:10.1016/j.chest.2016.04.036 · Cited by 11
Sex steroid receptor expression in idiopathic pulmonary fibrosis
Mehrad, M., Bittar, H. E. T., & Yousem, S. A. (2017) · Human Pathology · doi:10.1016/j.humpath.2017.02.012 · Cited by 11
Managing Idiopathic Pulmonary Fibrosis: Which Drug for Which Patient?
Hayton, C., & Chaudhuri, N. (2017) · Drugs & Aging · doi:10.1007/s40266-017-0488-0 · Cited by 14
Oldham, J. M., Witt, L. J., Adegunsoye, A., Chung, J. H., Lee, C. T., Hsu, S., Chen, L. W., Husain, A. N., Montner, S. M., Vij, R., et al. (2018) · BMC Pulmonary Medicine · doi:10.1186/s12890-018-0599-3 · Cited by 11
Economic consequences of idiopathic pulmonary fibrosis in Denmark
Hilberg, O., Bendstrup, E. M., Ibsen, R., et al. (2018) · ERJ Open Research · doi:10.1183/23120541.00045-2017 · Cited by 11
Harari, S. A., Caminati, A., Confalonieri, M., Poletti, V. E., Vancheri, C., Pesci, A., Rogliani, P., Luppi, F., Agostini, C., Rottoli, P., et al. (2019) · The Clinical Respiratory Journal · doi:10.1111/crj.12999 · Cited by 11
In vitro screening for compounds from Hypericum longistylum with anti-pulmonary fibrosis activity
Li, X., Liu, S., Zhai, Y., Cao, X., Gao, S., Huang, M., Guo, Y., Xie, C., & Zhou, H. (2019) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2019.126695 · Cited by 11
Resolving intestinal fibrosis through regenerative medicine
Schwab, R., Lim, R., & Goldberg, R. (2019) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2019.09.011 · Cited by 11
McLellan, T., George, P. M., Ford, P., Backer, J. D., Holsbeke, C. S. V., Mignot, B., Screaton, N. J., Ruggiero, A., & Thillai, M. (2020) · ERJ Open Research · doi:10.1183/23120541.00290-2019 · Cited by 11
Diridollou, T., Sohier, L., Rousseau, C., Angibaud, A., Chauvin, P., Gaignon, T., Tas, M., Lemerre, J., Kerjouan, M., Salé, A., et al. (2020) · Respiratory Medicine and Research · doi:10.1016/j.resmer.2020.02.004 · Cited by 14
“Chest CT-scan is now prominent in the management of those patients, in order to obtain an accurate, early diagnosis needed for treatment with the anti-fibrotic drug that have recently become available (3,4).”
BackgroundKølner-Augustson, L., Prior, T. S., Skivild, V., et al. (2020) · European Clinical Respiratory Journal · doi:10.1080/20018525.2020.1853658 · Cited by 11
“Survival is improved in patients receiving one of the two registered antifibrotic drugs, pirfenidone, and nintedanib [1,2,5,6] Fatigue is a central symptom in many diseases and a side effect of many medical treatments, including pirfenidone.”
BackgroundPycnogenol®-Centellicum® supplementation improves lung fibrosis and post-COVID-19 lung healing
CESARONE, M. R., Shu, H. U., BELCARO, G., CORNELLI, U., Feragalli, B., CORSI, M., BOMBARDELLI, E., COTELLESE, R., HOSOI, M., & ROSENKVIST, L. (2022) · Minerva Medica · doi:10.23736/s0026-4806.20.07225-0 · Cited by 11
Jiang, H., Zhao, Y., Tang, H., Duan, S., Li, M., Yang, X., Liu, J., Lou, X., Cai, Y., Zhao, W., et al. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105923 · Cited by 12
Scharm, S. C., Schaefer‐Prokop, C. M., Willmann, M., Vogel‐Claussen, J., Knudsen, L., Jonigk, D. D., Fuge, J., Welte, T., Wacker, F. K., Prasse, A., et al. (2022) · European Radiology · doi:10.1007/s00330-022-08702-w · Cited by 11
Chronic Lung Allograft Dysfunction: Evolving Concepts and Therapies
Amubieya, O., Ramsey, A. L., Derhovanessian, A., Fishbein, G. A., Lynch, J. P., Belperio, J. A., & Weigt, S. S. (2021) · Seminars in Respiratory and Critical Care Medicine · doi:10.1055/s-0041-1729175 · Cited by 11
Preferential PDE4B Inhibition — A Step toward a New Treatment for Idiopathic Pulmonary Fibrosis
Chambers, R. C. (2022) · New England Journal of Medicine · doi:10.1056/nejme2205411 · Cited by 13
Li, K., Liu, P., Zhang, W., Liu, X., Tanino, Y., Koga, Y., & Yan, X. (2022) · Annals of Translational Medicine · doi:10.21037/atm-22-3700 · Cited by 10
Kim, J., Chung, C., Cho, H. S., & Kim, H. C. (2023) · PLoS ONE · doi:10.1371/journal.pone.0281295 · Cited by 11
Thabut, G., Crestani, B., Porcher, R., & Richeldi, L. (2015) · European Respiratory Journal · doi:10.1183/13993003.02204-2014 · Cited by 10
Troy, L. K., Chapman, S. A., Lake, F., WILSHER, M. L., Honeysett, L., Macansh, S., & Corte, T. J. (2015) · Respirology · doi:10.1111/resp.12512 · Cited by 11
Longitudinal assessment of lung function decline in the occupational setting
Redlich, C. A., & Tarlo, S. M. (2015) · Current Opinion in Allergy and Clinical Immunology · doi:10.1097/aci.0000000000000153 · Cited by 12
Update in Interstitial Lung Disease 2014
Belloli, E. A., Martínez, F. J., & Flaherty, K. R. (2015) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201504-0768up · Cited by 9
The Role of Immunity and Inflammation in IPF Pathogenesis
Butler, M. W., & Keane, M. P. (2018) · Respiratory medicine · doi:10.1007/978-3-319-99975-3_6 · Cited by 12
Panchabhai, T. S., Arrossi, A. V., Highland, K. B., Bandyopadhyay, D., Culver, D. A., Budev, M. M., & Farver, C. F. (2019) · BMC Pulmonary Medicine · doi:10.1186/s12890-019-0778-x · Cited by 12
Comparing effectiveness of prognostic tests in idiopathic pulmonary fibrosis
Moua, T., Lee, A. S., & Ryu, J. H. (2019) · Expert Review of Respiratory Medicine · doi:10.1080/17476348.2019.1656069 · Cited by 10
Combined therapy with pirfenidone and nintedanib counteracts fibrotic silicosis in mice
Bai, L., Wang, J., Wang, X., Wang, J., Zeng, W., Pang, J., Zhang, T., Li, S., Song, M., Shi, Y., et al. (2024) · British Journal of Pharmacology · doi:10.1111/bph.17390 · Cited by 15
Kreuter, M., Maher, T. M., Wuyts, W. A., Valenzuela, C., Hamblin, M., Kim, S., Patel, A., Elpers, B., & Richeldi, L. (2025) · CHEST Journal · doi:10.1016/j.chest.2025.04.003 · Cited by 15
Idiopathic Pulmonary Fibrosis: Cellular Heterogeneity, Mechanisms, and Therapeutic Implications
Zuo, L., Liu, Q., Ye, D., Fan, J., & Wu, L. (2025) · MedComm · doi:10.1002/mco2.70521 · Cited by 20
Senhaji, L., Senhaji, N., Abbassi, M., Karhate, M., Serraj, M., Biaze, M. E., Benjelloun, M. C., Ouldim, K., Bouguenouch, L., & Amara, B. (2026) · Biomedicines · doi:10.3390/biomedicines14010090 · Cited by 14
Hot off the breath: a big step forward for idiopathic pulmonary fibrosis
Ryerson, C. J., & Collard, H. R. (2014) · Thorax · doi:10.1136/thoraxjnl-2014-205892 · Cited by 10
Shi, X., Yu, Z., Zhu, C., Jiang, L., Geng, N., Fan, X., Guan, Z., & Lu, X. Y. (2022) · RSC Medicinal Chemistry · doi:10.1039/d1md00403d · Cited by 11
Zhou, Y., Zhang, Y., Cheng, H., Li, X., Feng, D., Yue, S., Xu, J., Xie, H., & Luo, Z. (2022) · Biomedicines · doi:10.3390/biomedicines10112715 · Cited by 10
The Lung Transplant Candidate, Indications, Timing, and Selection Criteria
Mannem, H. C., Aversa, M. M., Keller, T., & Kapnadak, S. G. (2023) · Clinics in Chest Medicine · doi:10.1016/j.ccm.2022.10.001 · Cited by 13
CD4+LAG3+T cells are decreased in SSc-ILD and affect fibroblast mesenchymal transition by TGF-β3
Qin, L., Lin, H., Zhu, F., Wang, J., Feng, T., Xu, T., Zhang, G., & Zhang, X. (2023) · iScience · doi:10.1016/j.isci.2023.108225 · Cited by 11
Tanshinone IIA alleviates bleomycin-induced pulmonary fibrosis by inhibiting Zbtb16
Zhang, H., Qiu, J., Zhao, Q., Zhang, Y., Zheng, H., Dou, Z., & Yan, Y. (2024) · Pulmonary Pharmacology & Therapeutics · doi:10.1016/j.pupt.2024.102285 · Cited by 10
Enomoto, N. (2024) · Respiratory Investigation · doi:10.1016/j.resinv.2024.03.006 · Cited by 13
Promising advances in treatments for the management of idiopathic pulmonary fibrosis
Sofia, C., Comes, A., Sgalla, G., & Richeldi, L. (2024) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2024.2354460 · Cited by 10
Weng, C., Zhou, Y., Zhang, L., Wang, G., Ding, Z., Xue, L., & Liu, Z. (2024) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2024.152500 · Cited by 10
Pulmonary rehabilitation in idiopathic pulmonary fibrosis
Dowman, L., & Holland, A. E. (2024) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0000000000001094 · Cited by 12
Reccardini, N., Chernovsky, M., Salton, F., Confalonieri, P., Mondini, L., Barbieri, M., Romallo, A., Maggisano, M., Torregiani, C., Geri, P., et al. (2024) · Pharmaceuticals · doi:10.3390/ph17070930 · Cited by 11
Xu, J., Zhou, L., Chen, H., He, Y., Zhao, G., Li, L., Efferth, T., Ding, Z., & Shan, L. (2024) · Phytomedicine · doi:10.1016/j.phymed.2024.155871 · Cited by 11
Otilonium bromide ameliorates pulmonary fibrosis in mice through activating phosphatase PPM1A
Zhao, T., Zhou, Z., Wan, H., Feng, T., Hu, X.-H., Li, X., Zhao, S., Li, H., Hou, J., Li, W., et al. (2024) · Acta Pharmacologica Sinica · doi:10.1038/s41401-024-01368-8 · Cited by 13
Tanshinone IIA Loaded Inhaled Polymer Nanoparticles Alleviate Established Pulmonary Fibrosis
Chen, W., Gao, Y., Liu, Y., Luo, Y., Xue, X., Xiao, C., & Wei, K. (2024) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.4c00532 · Cited by 10
Babariya, H., Gaidhane, S., Acharya, S., & Kumar, S. (2024) · Cureus · doi:10.7759/cureus.70497 · Cited by 18
Birker, M., Boucher, M., Ranieri, G., Poirey, S., Studer, R. O., Freti, D., Schnoebelen, M., Froidevaux, S., Morrison, K., Wyss, C., et al. (2025) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/j.jpet.2025.103396 · Cited by 12
Sun, L., Zhang, H., Jiang, H., Li, W., Li, M., Yang, X.-Y., Cai, Y., Xue, K.-K., Gou, Y., Liu, X., et al. (2025) · Acta Pharmacologica Sinica · doi:10.1038/s41401-025-01488-9 · Cited by 13
Takashima, T., Zeng, C., Murakami, E., Fujiwara, N., Kohara, M., Nagata, H., Feng, Z., Sugai, A., Harada, Y., Ichijo, R., et al. (2025) · JCI Insight · doi:10.1172/jci.insight.187172 · Cited by 12
Gao, Y., Wei, T., Mu, L., Liu, C., Zeng, Y., Guo, X., Zhang, Y., Yuan, Z., & Cheng, J. (2025) · Phytomedicine · doi:10.1016/j.phymed.2025.156785 · Cited by 14
Aono, Y., Nakamura, Y., Kono, M., Nakamura, H., Yokomura, K., Imokawa, S., Toyoshima, M., Yasui, H., Hozumi, H., Karayama, M., et al. (2020) · Therapeutic Advances in Respiratory Disease · doi:10.1177/1753466620953783 · Cited by 10
Bi, Y., Rekić, D., Paterniti, M. O., Chen, J., Marathe, A., Chowdhury, B. A., Karimi-Shah, B. A., & Wang, Y. (2020) · Journal of Pharmacokinetics and Pharmacodynamics · doi:10.1007/s10928-020-09718-9 · Cited by 10
Interstitial Lung Diseases and the Impact of Gender
Karampitsakos, Τ., Παπαϊωάννου, Ο., Katsaras, M., Sampsonas, F., & Τzouvelekis, Α. (2021) · Clinics in Chest Medicine · doi:10.1016/j.ccm.2021.04.011 · Cited by 10
An Overview of Herbal Medicines for Idiopathic Pulmonary Fibrosis
Murthy, P., Shaibie, N. A., Lim, C. L., Ling, A. P. K., Chye, S. M., & Koh, R. Y. (2022) · Processes · doi:10.3390/pr10061131 · Cited by 9
Huang, T., & He, W.-Y. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.890530 · Cited by 10
Pregnancy Considerations for Patients With Interstitial Lung Disease
Grant-Orser, A., Metcalfe, A., Pope, J. E., & Johannson, K. A. (2022) · CHEST Journal · doi:10.1016/j.chest.2022.06.024 · Cited by 11
Nguyen, V., Pan, F., Zhang, G., Zhang, Q., & Lu, Y. (2022) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2022/3744618 · Cited by 13
“PF has extensive extracellular matrix deposition, myofibroblast accumulation, and lung remodeling [1, 2].”
BackgroundMájek, O., Gregor, J., Moğulkoç, N., Lewandowska, K. B., Šterclová, M., Müller, V., Hájková, M., Kramer, M. R., Tekavec-Trkanjec, J., Jovanović, D. M., et al. (2022) · PLoS ONE · doi:10.1371/journal.pone.0273854 · Cited by 11
Chen, Y., Bai, Z., Zhang, Z., Hu, Q., Zhong, J., & Dong, L. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.978429 · Cited by 12
“As reported, the most common adverse events of pirfenidone were gastrointestinal-related nausea and dyspepsia, which are generally responsive to dosage reduction (15, 16, 30).”
BackgroundMethodVISTA (PD-1H) Is a Crucial Immune Regulator to Limit Pulmonary Fibrosis
Kim, S., Adams, T. S., Hu, Q., Shin, H. J., Chae, G., Lee, S. E., Sharma, L., Kwon, H., Lee, F. Y., Park, H., et al. (2022) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2022-0219oc · Cited by 9
Deciphering the Antifibrotic Property of Metformin
Septembre‐Malaterre, A., Boina, C., Douanier, A., & Gasque, P. (2022) · Cells · doi:10.3390/cells11244090 · Cited by 12
Sarkar, A., Das, S., Bone, H., DeVengencie, I., Prasad, J. M. N., Farkas, D., Londino, J. D., Nho, R. S., Rojas, M. M., & Horowitz, J. C. (2023) · The Journal of Immunology · doi:10.4049/jimmunol.2200511 · Cited by 9
Diagnosis and Pharmacologic Management of Fibrotic Interstitial Lung Disease
Berger, K., & Kaner, R. J. (2023) · Life · doi:10.3390/life13030599 · Cited by 12
“The phase III RCT INBUILD assigned patients with non-IPF fibrosing lung diseases who met the study-specific criteria for ILD progression to receive nintedanib versus placebo.”
BackgroundResultInfluentialQing, K., Altes, T. A., Mugler, J. P., Mata, J. F., Tustison, N. J., Ruppert, K., Bueno, J., Flors, L., Shim, Y. M., Zhao, L., et al. (2023) · Biomedicines · doi:10.3390/biomedicines11061533 · Cited by 10
“Nindetanib and pirfenidone [7,8] reduce the rate of progression in lung function decline and may improve mortality in IPF [9], but it is not known whether they are more or less effective in specific subsets of patients.”
BackgroundYamada, T., Nakashima, T., Masuda, T., Sakamoto, S., Yamaguchi, K., Horimasu, Y., Miyamoto, S., Iwamoto, H., Fujitaka, K., Hamada, H., et al. (2023) · The Journal of Pathology · doi:10.1002/path.6169 · Cited by 12
Approach to Clinical Trials for the Prevention of Pulmonary Fibrosis
Kim, J. S., Montesi, S. B., Adegunsoye, A., Humphries, S. M., Salisbury, M. L., Hariri, L. P., Kropski, J. A., Richeldi, L., Wells, A. U., Walsh, S. L. F., et al. (2023) · Annals of the American Thoracic Society · doi:10.1513/annalsats.202303-188ps · Cited by 11
Osteopontin: an essential regulatory protein in idiopathic pulmonary fibrosis
Zhu, X., Ji, J., & Han, X. (2023) · Journal of Molecular Histology · doi:10.1007/s10735-023-10169-y · Cited by 12
Duke, J. D., Roy, M., Daley, S., Hoult, J. P., Benzo, R., & Moua, T. (2024) · ERJ Open Research · doi:10.1183/23120541.00591-2023 · Cited by 12
García‐Manso, I. G., Arenas-Jiménez, J. J., Blasco, L., García‐Garrigós, E., Pérez, E. N., Matilla, M. S., Ruiz‐Alcaraz, S., & Sevila, R. G. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e26623 · Cited by 11
Therapeutic Strategies for Idiopathic Pulmonary Fibrosis – Thriving Present and Promising Tomorrow
Gupta, N., Paryani, M., Patel, S. S., Bariya, A. H., Srivastava, A., Pathak, Y. V., & Butani, S. (2024) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.2408 · Cited by 11
TOLLIP SNP and Antimicrobial Treatment Effect in Idiopathic Pulmonary Fibrosis
Whalen, W., Berger, K., Kim, J. S., Simmons, W., Ma, S., Kaner, R. J., Martínez, F. J., Anstrom, K. J., Parfrey, H., Maher, T. M., et al. (2024) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202312-2224le · Cited by 12
Orphan drug approvals of 2014: Europe and the United States
Norman, P. (2015) · Expert Opinion on Orphan Drugs · doi:10.1517/21678707.2015.1022530 · Cited by 10
Update in Diffuse Parenchymal Lung Disease 2013
Rosas, I. O., & Kaminski, N. (2015) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201405-0856up · Cited by 9
A retrospective chart review of pirfenidone-treated patients in Sweden: the REPRIS study
Sköld, C. M., Janson, C., Elf, Å. K., et al. (2016) · European Clinical Respiratory Journal · doi:10.3402/ecrj.v3.32035 · Cited by 10
Idiopathic pulmonary fibrosis: current and future directions
Soo, E., Adamali, H. I., & Edey, A. (2017) · Clinical Radiology · doi:10.1016/j.crad.2016.12.014 · Cited by 10
Efficacy and adverse events of pirfenidone in treating idiopathic pulmonary fibrosis
Ren, H. J., Wang, K., Yang, H., & Gao, L. (2017) · Saudi Medical Journal · doi:10.15537/smj.2017.9.19349 · Cited by 10
Formulation for a novel inhaled peptide therapeutic for idiopathic pulmonary fibrosis
Surasarang, S. H., Florova, G., Komissarov, A. A., Shetty, S., Idell, S., & Williams, R. O. (2017) · Drug Development and Industrial Pharmacy · doi:10.1080/03639045.2017.1371736 · Cited by 10
Idiopathic pulmonary fibrosis in a Swiss interstitial lung disease reference centre
Guler, S. A., Zumstein, P., Berezowska, S., Pöllinger, A., Geiser, T., & Funke-Chambour, M. (2018) · Swiss Medical Weekly · doi:10.4414/smw.2018.14577 · Cited by 10
Brownback, K. R., Pitts, L. R., & Abhyankar, S. (2018) · Bone Marrow Transplantation · doi:10.1038/s41409-018-0182-9 · Cited by 10
Diffuse Alveolar Hemorrhage Following Pirfenidone Initiation
Dull, S. K., Jagan, N., Moore, D. R., DePew, Z. S., Morrow, L. E., & Malesker, M. A. (2019) · Journal of Pharmacy Practice · doi:10.1177/0897190019841731 · Cited by 10
Kono, M., Nakamura, Y., Enomoto, N., Saito, G., Koyanagi, Y., Miyashita, K., Tsutsumi, A., Kobayashi, T., Yasui, H., Hozumi, H., et al. (2019) · Respiratory Investigation · doi:10.1016/j.resinv.2019.07.003 · Cited by 11
Rasky, A. J., Habiel, D. M., Morris, S. B., Schaller, M. A., Moore, B. B., Phan, S. H., Kunkel, S. L., Phillips, M., Hogaboam, C. M., & Lukacs, N. W. (2019) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00114.2019 · Cited by 11
Jiang, N., Zhou, Y., Zhu, M., et al. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.111904 · Cited by 10
Cheng, W., Wang, F., Feng, A., Li, X., & Yu, W. (2020) · BioMed Research International · doi:10.1155/2020/7840652 · Cited by 10
“In 2014, the US Food and Drug Administration(FDA-) approved nintedanib [2] and pirfenidone [3] may slow down the decline in lung function in patients with IPF but cannot change the IPF survival rate.”
BackgroundSuehs, C., BOURDIN, A. A., Vachier, I., et al. (2020) · Annals of Translational Medicine · doi:10.21037/atm-20-2814 · Cited by 10
Oxygen for interstitial lung diseases
Khor, Y. H., Smith, D. J. F., Johannson, K. A., & Renzoni, E. A. (2020) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0000000000000691 · Cited by 11
Rahaghi, F., Safdar, Z., Brown, A. W., de Andrade, J. A., Flaherty, K. R., Kaner, R. J., King, C. S., Padilla, M. L., Noth, I., Scholand, M. B., et al. (2020) · BMC Pulmonary Medicine · doi:10.1186/s12890-020-01209-4 · Cited by 10
Self-citationWhat parameters can be used to identify early idiopathic pulmonary fibrosis?
Mori, Y., & Kondoh, Y. (2020) · Respiratory Investigation · doi:10.1016/j.resinv.2020.10.008 · Cited by 13
TANAKA, M., Idei, M., Sakaguchi, H., Kato, R., Sato, D., Sawanobori, K., Kawarasaki, S., Hata, T., Yoshizaki, A., Nakamura, M., et al. (2021) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.14749 · Cited by 11
Cardiovascular safety of the tyrosine kinase inhibitor nintedanib
Ameri, P., Tini, G., Spallarossa, P., Mercurio, V., Tocchetti, C. G., & Porto, I. (2021) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.14793 · Cited by 11
Kim, G. H. J., Shi, Y., Yu, W., & Wong, W. K. (2021) · Contemporary Clinical Trials · doi:10.1016/j.cct.2021.106333 · Cited by 11
Metadata
- Authors
- King, T. E., Bradford, W. Z., Castro-Bernardini, S., Fagan, E. A., Glaspole, I., Glassberg, M. K., Gorina, E., Hopkins, P. M., Kardatzke, D., Lancaster, L., Lederer, D. J., Nathan, S. D., Pereira, C. A., Sahn, S. A., Sussman, R., Swigris, J. J., & Noble, P. W.
- Affiliations
- Cedars-Sinai Medical Center (US)
- The Alfred Hospital (AU)
- University of Miami (US)
- Prince Charles Hospital (AU)
- Vanderbilt University Medical Center (US)
- Columbia University Irving Medical Center (US)
- Inova Fairfax Hospital (US)
- Universidade Federal de São Paulo (BR)
- Medical University of South Carolina (US)
- Overlook Medical Center (US)
- National Jewish Health (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2014-05-29
- Volume
- 370
- Issue
- 22
- Pages
- 2083-2092
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2168666423
- Cited by
- 3,975
- References
- 27
- Citations by year
- 2026: 272 · 2025: 303 · 2024: 371 · 2023: 315 · 2022: 339 · 2021: 412 · 2020: 343 · 2019: 310 · 2018: 335 · 2017: 319 · 2016: 288 · 2015: 279 · 2014: 76
- FWCI
- 256.80
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- UNIFESP Institutional Repository (Universidade Federal de São Paulo) (submittedVersion)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Chronic Obstructive Pulmonary Disease (COPD) Research
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Pulmonary Hypertension Research and Treatments
- Keywords
- pirfenidone, idiopathic pulmonary fibrosis, antifibrotic therapy, forced vital capacity decline, disease progression, mortality, progression-free survival, 6-minute walk distance, dyspnea, gastrointestinal adverse effects, cutaneous adverse events, exercise tolerance, lung function decline, safety and tolerability
- MeSH terms
- Administration, Oral, Adult, Aged, Aged, 80 and over, Antifibrinolytic Agents, Double-Blind Method, Enzyme Inhibitors, Female, Humans, Male, Middle Aged, Pyridones, Vital Capacity, Treatment Outcome, Disease Progression, Idiopathic Pulmonary Fibrosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.